Brief Review of Remdesivir for 5 or 10 Days in Severe COVID19— Goldman 2020

This is a brief audio review. In the article Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 published, 2020 by Goldman and Colleagues, The outcomes and key points are as noted: A 10 day course of remdesivir is not better or worse than a 5 day course of remdesivir in patients with severe COVID19 without mechanical ventilation. Day 14 Clinical status on a 7 point ordinal scale measured frequencies of patients in clinical status groups ranging from not hospitalized to death, and showed no differences after tabulating 397 patients, p=0.14 per the Wilcoxon Rank Sum Test accounting for clinical baseline status. This was a Phase 3, Randomized controlled trial, open label with 397 patients who were patients with severe COVID19, radiographic pneumonia, with oxygen saturation of 94% or less while not on supplemental oxygenation and not on mechanical ventilation.

Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, Spinner CD, Galli M, Ahn MY, Nahass RG, Chen YS, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wei X, Gaggar A, Brainard DM, Towner WJ, Muñoz J, Mullane KM, Marty FM, Tashima KT, Diaz G, Subramanian A; GS-US-540-5773 Investigators. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020 Nov 5;383(19):1827-1837. doi: 10.1056/NEJMoa2015301. Epub 2020 May 27. PMID: 32459919; PMCID: PMC7377062.